Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States.
Case Western Reserve University, Cleveland, OH 44106, United States.
Diabetes Res Clin Pract. 2021 May;175:108825. doi: 10.1016/j.diabres.2021.108825. Epub 2021 Apr 20.
Given the shift from use of less expensive human to costlier analog insulins for treatment of type 2 diabetes (T2D), we examine characteristics and glycemic control associated with type of basal insulin use.
We analyzed respondents with T2D in six consecutive National Health and Nutrition Examination Survey (NHANES) cycles (2005-2016). Logistic regression models examined associations between demographics, socioeconomic factors, and NHANES cycle with (1) type of basal insulin use and (2) hemoglobin A1c <8.0% and <7.0% according to basal insulin type.
Basal insulin use increased from 9.6% to 17.2% of respondents with T2D between 2005 and 2016. Among 723 respondents meeting inclusion criteria, the proportion using analog basal insulin rose from 58% to 88%. African American (aOR 0.42, 95% CI 0.24-0.74) and Hispanic (aOR 0.54, 95% CI 0.30-0.96) respondents had lower odds of analog basal insulin use than non-Hispanic White respondents in adjusted and unadjusted models. Older age and having health insurance, but not type of basal insulin use, associated with meeting HbA1c targets.
Non-White NHANES respondents were less likely to use analog basal insulin than White respondents. Increased analog basal insulin use between 2005 and 2016 was not associated with improved glycemic control.
由于治疗 2 型糖尿病(T2D)时从使用较便宜的人胰岛素转为使用更昂贵的胰岛素类似物,我们研究了与基础胰岛素使用类型相关的特征和血糖控制情况。
我们分析了连续六次国家健康与营养调查(NHANES)周期(2005-2016 年)中患有 T2D 的受访者。逻辑回归模型根据基础胰岛素类型,研究了人口统计学、社会经济因素和 NHANES 周期与(1)基础胰岛素使用类型(2)血红蛋白 A1c<8.0%和<7.0%之间的关联。
2005 年至 2016 年间,T2D 患者中使用基础胰岛素的比例从 9.6%增加到 17.2%。在符合纳入标准的 723 名受访者中,使用胰岛素类似物基础胰岛素的比例从 58%上升到 88%。与非西班牙裔白人受访者相比,非裔美国人(aOR 0.42,95%CI 0.24-0.74)和西班牙裔(aOR 0.54,95%CI 0.30-0.96)受访者使用胰岛素类似物基础胰岛素的可能性较低,调整后和未调整模型均如此。年龄较大和有医疗保险,但不是基础胰岛素类型,与达到 HbA1c 目标相关。
与白人受访者相比,非裔 NHANES 受访者使用胰岛素类似物基础胰岛素的可能性较小。2005 年至 2016 年间,胰岛素类似物基础胰岛素使用量的增加与血糖控制改善无关。